SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with ...
People with uncontrolled movement problems can have a harder time doing everyday tasks such as speaking, reading, writing, and cooking, which can cause a loss of independence. This may cause people to ...
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile ...
Please provide your email address to receive an email when new articles are posted on . The new once-daily tablet strength doses are 30 mg, 36 mg, 42 mg and 48 mg. Symptom improvement in tardive ...
In a study on treatments and outcomes in patients with Sydenham chorea (SC), corticosteroids were associated with faster resolution, while antibiotics, corticosteroids, and sodium valproate were ...
Xenazine (tetrabenazine) is a prescription drug that’s used to treat chorea, a movement disorder that can occur in people with Huntington’s disease. The drug comes as an oral tablet. It’s usually ...
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
This type of medication can help manage the uncontrolled movements that can occur with Huntington’s disease. Huntington’s disease is a neurodegenerative disorder that causes a progressive breakdown of ...
NEW YORK (Reuters Health) - Group A streptococcal infection appears to be associated with changes in behavior and the development of a movement disorder in elementary school children, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results